Review: taking Miralax and Zofran together


Summary

Drug interactions are reported among people who take Miralax and Zofran together. This review analyzes the effectiveness and drug interactions between Miralax and Zofran. It is created by eHealthMe based on reports of 54 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Miralax and Zofran >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Miralax

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. (latest outcomes from Miralax 8,713 users)

Zofran

Zofran has active ingredients of ondansetron hydrochloride. It is often used in post procedural nausea. (latest outcomes from Zofran 7 users)

On Jul, 28, 2016

54 people who take Miralax, Zofran are studied.


Number of reports submitted per year:

Miralax and Zofran drug interactions.

Drug effectiveness over time:

Miralax:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Zofran:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Miralax:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)
Zofran:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Miralax:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Zofran:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • blood bilirubin increased
  • engraftment syndrome
  • renal failure acute
  • colitis
  • acute graft versus host disease in liver
  • respiratory failure
  • graft versus host disease
  • abdominal pain
  • cerebral infarction
  • dehydration
not specified:
  • anxiety
  • fatigue
  • neutropenia
  • general physical health deterioration
  • abdominal pain upper
  • confusional state
  • phlebitis
  • disease progression
  • anaemia
  • asthenia

Most common drug interactions by gender *:

female:
  • fatigue
  • nausea
  • anxiety
  • depression
  • pneumonia
  • disease progression
  • colitis
  • anaemia
  • arthralgia
  • constipation
male:
  • neutropenia
  • phlebitis
  • confusional state
  • abdominal pain upper
  • general physical health deterioration
  • jugular vein thrombosis
  • thrombocytopenia
  • anxiety
  • asthenia
  • haemoglobin decreased

Most common drug interactions by age *:

10-19:
  • blood bilirubin increased
  • engraftment syndrome
  • renal failure acute
  • acute graft versus host disease in liver
  • respiratory failure
  • graft versus host disease
30-39:
  • enterocolitis
  • abdominal discomfort
  • abdominal distension
  • abdominal pain upper
  • acute respiratory distress syndrome
  • anhedonia
  • anisocytosis
  • anxiety
  • asthenia
  • back pain
40-49:
  • cerebrovascular accident
  • disease progression
  • ischaemic stroke
  • blood culture positive
  • deep vein thrombosis
  • endocarditis
  • general physical health deterioration
  • hypoxia
  • staphylococcal infection
  • visual field defect
50-59:
  • fatigue
  • anaemia
  • anxiety
  • colitis
  • constipation
  • decreased appetite
  • depression
  • headache
  • hyperkalaemia
  • insomnia
60+:
  • asthenia
  • weight decreased
  • anxiety
  • general physical health deterioration
  • neutropenia
  • confusional state
  • phlebitis
  • abdominal pain upper
  • jugular vein thrombosis
  • thrombocytopenia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Miralax and Zofran?

Can you answer these questions?

More questions for: Miralax, Zofran

You may be interested in these reviews

More reviews for: Miralax, Zofran

On eHealthMe, Miralax (polyethylene glycol 3350) is often used to treat constipation. Zofran (ondansetron hydrochloride) is often used to treat post procedural nausea. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.